Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Damodaran, 2019, Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches., J Urol, 201, 876, 10.1097/JU.0000000000000117
Nuhn, 2019, Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology., Eur Urol, 75, 88, 10.1016/j.eururo.2018.03.028
Iyengar, 2018, Consolidative radiotherapy for limited metastatic non–small-cell lung cancer: a phase 2 randomized clinical trial., JAMA Oncol, 4, 10.1001/jamaoncol.2017.3501
Gomez, 2019, Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study., J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201
Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial., Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5
Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial., Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3
Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial., J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853
Loo, 2019, SABR-COMET: harbinger of a new cancer treatment paradigm., Lancet, 393, 2013, 10.1016/S0140-6736(19)30278-8
Lussier, 2011, MicroRNA expression characterizes oligometastasis(es)., PLoS One, 6, 10.1371/journal.pone.0028650
Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs., PLoS One, 7, 10.1371/journal.pone.0050141
Uppal, 2015, 14q32-Encoded microRNAs mediate an oligometastatic phenotype., Oncotarget, 6, 3540, 10.18632/oncotarget.v6i6
Pitroda, 2018, Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis., Nat Commun, 9, 1793, 10.1038/s41467-018-04278-6
Chaudhuri, 2017, Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling., Cancer Discov, 7, 1394, 10.1158/2159-8290.CD-17-0716
Tie, 2019, Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study., Gut, 68, 663, 10.1136/gutjnl-2017-315852
Wyatt, 2017, Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer., J Natl Cancer Inst, 109, 10.1093/jnci/djx118
Hong, 2018, Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis., PLoS One, 13, 10.1371/journal.pone.0195149
Weichselbaum, 2018, The 46th David A. Karnofsky Memorial Award Lecture: oligometastasis—from conception to treatment., J Clin Oncol, 36, 3240, 10.1200/JCO.18.00847
Formenti, 2018, Radiotherapy induces responses of lung cancer to CTLA-4 blockade., Nat Med, 24, 1845, 10.1038/s41591-018-0232-2
Benedict, 2010, Stereotactic body radiation therapy: the report of AAPM Task Group 101., Med Phys, 37, 4078, 10.1118/1.3438081
Abida, 2019, Genomic correlates of clinical outcome in advanced prostate cancer., Proc Natl Acad Sci U S A, 116, 11428, 10.1073/pnas.1902651116
Annala, 2018, Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer., Cancer Discov, 8, 444, 10.1158/2159-8290.CD-17-0937
Na, 2017, Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death., Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033
Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer., Nature, 520, 353, 10.1038/nature14347
Vandekerkhove, 2019, Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer., Eur Urol, 75, 667, 10.1016/j.eururo.2018.12.042
Duchesne, 2016, Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial., Lancet Oncol, 17, 727, 10.1016/S1470-2045(16)00107-8
Moul, 2004, Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy., J Urol, 171, 1141, 10.1097/01.ju.0000113794.34810.d0
Studer, 2006, Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891., J Clin Oncol, 24, 1868, 10.1200/JCO.2005.04.7423
Golden, 2015, Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial., Lancet Oncol, 16, 795, 10.1016/S1470-2045(15)00054-6
Soldatov, 2019, Patterns of progression after 68Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer., Int J Radiat Oncol Biol Phys, 103, 95, 10.1016/j.ijrobp.2018.08.066
Surveillance, Epidemiology, and End Results Program. Cancer stat facts: prostate cancer. Accessed January 28, 2020. https://seer.cancer.gov/statfacts/html/prost.html